Epirium Bio

Epirium Bio is a private, clinical-stage biotech founded in 2008, focused on a novel platform targeting mitochondrial biogenesis and function via PGE-2 signaling. The company's most advanced asset, MF-300, is in Phase 2b for sarcopenia, with earlier-stage programs exploring indications like Becker muscular dystrophy, spinal muscular atrophy, and idiopathic pulmonary fibrosis. Led by CEO Russell J. Cox and backed by an $85M Series A, Epirium is advancing its pipeline of oral therapies for diseases with significant unmet need.

IP-protected platform of orally bioavailable small molecules that leverage PGE-2 signaling to restore tissue homeostasis by resolving inflammation, stimulating regeneration, and reducing fibrosis, with a novel mechanism linked to mitochondrial biogenesis and function.

In sarcopenia, competition includes other biotechs and large pharma companies developing myostatin inhibitors, SARMs, and other anabolic agents. In neuromuscular diseases, companies like Sarepta and Pfizer are leaders, but Epirium's oral, mitochondrial-focused mechanism offers a differentiated approach. The fibrotic disease space is crowded with both small molecules and biologics.